Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis-Reference-Cited by-同舟云学术

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis

Published:2017-03-28 Issue:10 Volume:116 Page:1247-1253
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Pelzer Uwe,Blanc Jean-Frédéric,Melisi Davide,Cubillo Antonio,Von Hoff Daniel D,Wang-Gillam Andrea,Chen Li-Tzong,Siveke Jens T,Wan Yin,Solem Caitlyn T,Botteman Marc F,Yang Yoojung,de Jong Floris A,Hubner Richard A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201767.pdf

Reference22 articles.

1. Chen L-T, Von Hoff DD, Li C-P, Wang-Gillam A, Bodoky G, Dean AP, Shan Y-S, Jameson GS, Macarulla T, Lee K-H (2015) Expanded analyses of napoli-1: phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol 33: 234.

2. Cole BF, Gelber RD (1995) A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. Stat Med 14: 1771–1784.

3. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem J, Conroy T (2015) Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26: v56–v68.

4. Fairclough DL (2010) Design and Analysis of Quality of Life Studies in Clinical Trials. CRC Press.

5. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49 (6): 1374–1403.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Development of Vesicular Carrier for Transdermal Drug Delivery: A Review;Jordan Journal of Pharmaceutical Sciences;2024-03-19

2. Estimating Optimal Individualized Treatment Rules with Multistate Processes;Biometrics;2023-04-04

3. Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan;Journal of Pharmaceutical Sciences;2023-02

4. Quality-Adjusted Survival in Patients with Recurrence of Breast Cancer Diagnosed by Asymptomatic or Symptomatic Opportunities;The Kurume Medical Journal;2022-12-31

5. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial;Therapeutic Advances in Medical Oncology;2022-01